The majority of the US Food and Drug Administration’s Oncologic Drugs Advisory Committee agreed with the agency that the benefits of Spectrum Pharmaceuticals Inc.’s Pozenveo (poziotinib) for a rare form of lung cancer do not outweigh its risks, citing its lack of meaningful benefit over currently available therapies, uncertain dosing, and delay in initiation of a confirmatory trial.
But the 9-4 vote at the committee’s 22 September meeting shows that many members are willing to accept issues with...





